药师干预降低万古霉素相关急性肾损伤的系统综述与荟萃分析
AIMS: The aim was to quantify the relationship between pharmacist intervention and vancomycin-associated acute kidney injury (AKI). METHODS: Electronic databases were searched up to August 2020 for meta-analyses of cohort studies and/or randomized controlled trials.…
要点
- 药师干预使万古霉素相关AKI发生率从9.6%降至7.3%(OR 0.52)。
- 干预后达标浓度率显著提高(OR 2.86),血肌酐检测率提高(OR 3.24)。
- 干预后患者死亡风险显著降低(OR 0.47,95%CI 0.31-0.72)。
核心结论
- 药师干预万古霉素治疗可显著降低万古霉素相关AKI发生率,同时提高疗效并降低死亡率。
研究设计与样本
- 系统综述与荟萃分析,检索电子数据库至2020年8月,纳入比较药师干预前后患者AKI发生率的队列研究和/或随机对照试验。
临床怎么用
- 药师应参与万古霉素治疗管理,通过优化给药方案、监测谷浓度和肾功能来降低AKI风险。
- 临床药师干预可提高万古霉素达标浓度率和血肌酐监测率,并可能降低死亡率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim was to quantify the relationship between pharmacist intervention and vancomycin-associated acute kidney injury (AKI). METHODS: Electronic databases were searched up to August 2020 for meta-analyses of cohort studies and/or randomized controlled trials. Studies that compared the incidence of AKI in patients between post- and prepharmacist intervention were investigated. The primary outcome was incidence of AKI. We also evaluated the influence of pharmacist intervention in risk factors of vancomycin-associated AKI. RESULTS: The search strategy retrieved 1744 studies and 34 studies with 19 298 participants were included (22 published articles and 12 abstracts from conference proceedings). Compared with the preintervention group, the postintervention group patients had a significantly lower incidence of vancomycin-associated AKI: 7.3% for post- and 9.6% for preintervention (odds ratio [OR] 0.52, 95% confidence interval [CI]; 0.41, 0.67], P < .00001). The rate of attaining target concentration was significantly higher in the post- than preintervention group (OR 2.86, 95% CI [2.23, 3.67], P < .00001). The postintervention group significantly improved the percentage of serum creatinine laboratory tests than preintervention group (OR = 3.24, 95% CI 2.02, 5.19], P < .00001). Patients postintervention had markedly lower risk of mortality than preintervention patients (OR 0.47, 95% CI [0.31, 0.72], P = .0004). CONCLUSION: Pharmacist intervention in vancomycin treatment significantly decreased the rate of vancomycin-associated AKI, while improving efficacy and reducing mortality. We speculate that this is because the pharmacist interventions optimized the rationality of vancomycin therapy, monitoring of vancomycin trough concentration and the monitoring of patients' renal function.
引用
- Kunming P, Xiaotian J, Qing X, et al. Impact of pharmacist intervention in reducing vancomycin-associated acute kidney injury: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022. PMID: 35285970. doi:10.1111/bcp.15301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。